Citations

Clear

7 citation(s) found for "Silveira, Marina".

Induction of Antigen-Specific T Cell Tolerance by CNP-104 Positively Affects Clinical Response in Primary Biliary Cholangitis (PBC) 9237
Elhofy, Adam, Frey, Molly , McCarthy, Derrick , Wambre, Erik , Caldwell, Stephen H. , Firpi-Morell, Roberto , Fortune, Brett E. , Galambos, Michael, Harnois, Denise M. , Hassanein, Tarek , Läwitz, E., Patel, Bhaktasharan, Phillips, Raymond E. , Pratt, Daniel S. , Pruthi, Jatinder, Rajendiran, Govarthanan , Reddy, Gautham, Rodrı́guez, Manuel, Silveira, Marina , Zervos, Bobby, Peloso, Paul M. , Gershwin, M. Eric, Bowlus, Christopher L. , Gordon, Stuart J. G. , Kappus, Matthew R. , Mchenry, Scott A. , Phillips, Raymond, Rodriguez, Manuel, Silveira, Marina

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.2663 Get It

Abstract Description PBC is an archetypal autoimmune disease where the dominant autoantigen is mitochondrial PDC-E2. Hitherto, PBC treatment has been neither specific nor directed toward restoration of tolerance. CNP-104, a tolerogenic nanoparticle encapsulating PDC-E2, is hypothesized to restore tolerance to pathogenic T cells. We conducted a Phase 2a First-in-Human randomized controlled trial of CNP-104 in PBC patients unresponsive/intolerant to ursodeoxycholic acid. The 42 enrolled subjects were randomized 2:1 to receive two doses of CNP-104 or placebo (PBO) one week apart and were followed for 120 days to assess safety and treatment durability. CNP-104 was safe and well-tolerated. Compared to PBO, the CNP-104 group had a reduced percentage of antigen-specific Th17 T cells and increased antigen-specific tolerogenic CD8+ T cell counts (TIGIT, GARP). ALP, ALT, and total bilirubin were similar between groups. Clinically relevant effects on albumin levels, liver stiffness, and the rate of change in 5-year UK-PBC risk for liver outcomes were improved in the CNP-104 group compared to PBO. This trial is limited by small size and data variability. Induction of antigen-specific T cell tolerance, shown by reduced Th17 cells and increased TIGIT and GARP cells correlates with improved liver stiffness, albumin, and UK-PBC. These findings suggest the CNP-104 tolerogenic mechanism of action translates to clinical benefits. These data support future studies with this unique therapeutic platform to treat PBC. Topic Categories Therapeutic Approaches to Autoimmunity (THER)
Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis
Ali, Ahmad H. , Tabibian, James H. , Nasser‐Ghodsi, Navine , Lennon, Ryan J. , DeLeon, Thomas, Hilscher, Moira , Silveira, Marina G., Carey, Elizabeth J. , Lindor, Keith D. , Ali, Ahmad Hassan, Borad, Mitesh J. , Tabibian, James H

Mayo Clinic

Hepatology | December 16, 2017 | Volume: 67 | Issue: 6 | Pages: 2338-2351

10.1002/hep.29730 | PMID 29244227 Get It

Primary sclerosing cholangitis (PSC) is a risk factor for cholangiocarcinoma (CCA) and gallbladder carcinoma (GBCa). Surveillance for GBCa is recommended, but the clinical utility of surveillance for other hepatobiliary cancers (HBCa) in PSC, namely CCA and hepatocellular carcinoma (HCC), remains unclear. We aimed to determine whether surveillance is associated with better survival after diagnosis of HBCa in patients with PSC. Medical records of PSC patients seen at the Mayo Clinic Rochester from 1995 to 2015 were reviewed. Patients were included if they had ≥1 year of follow‐up and developed HBCa. Patients were categorized according to their surveillance status (abdominal imaging, carbohydrate antigen 19‐9, and alpha‐fetoprotein). The primary endpoints were HBCa recurrence, HBCa‐related death, and all‐cause mortality. Overall survival was assessed by the Kaplan‐Meier survival method; HBCa‐related survival was assessed using competing risk regression. Tests of significance were two‐tailed, and a P value <0.05 was considered statistically significant. From 1995 to 2015, a total of 79 of 830 PSC patients were diagnosed with HBCa. Cumulative follow‐up was 712 and 283 person‐years pre‐ and post‐HBCa diagnosis, respectively. Seventy‐eight percent of patients (54/79) developed CCA, 21% (17/79) HCC, 6% (5/79) GBCa, 3% (2/79) both CCA and HCC, and 1% (1/79) both HCC and GBCa. Fifty‐one percent (40/79) were under HBCa surveillance, and 49% (39/79) were not. Patients in the surveillance group had significantly higher 5‐year overall survival (68% versus 20%, respectively; P < 0.001) and significantly lower 5‐year probability of experiencing an HBCa‐related adverse event (32% versus 75%, respectively; P < 0.001) compared with the no‐surveillance group. Conclusion: This study demonstrates that HBCa surveillance significantly improves outcomes, including survival, in patients with PSC. (Hepatology 2018;67:2338‐2351).
Investigational drugs in phase II clinical trials for primary biliary cholangitis
Silveira, Marina G., Lindor, Keith D.

Mayo Clinic

Expert Opinion on Investigational Drugs | August 24, 2017 | Volume: 26 | Issue: 10 | Pages: 1115-1121

10.1080/13543784.2017.1371135 | PMID 28836457 Get It

A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis
Silveira, Marina G., Gossard, Andrea A., Stahler, Alisha C., Jorgensen, Roberta A., Petz, Janice L., Ali, Ahmad H. , Lindor, Keith D.

Mayo Clinic

American Journal of Therapeutics | May 12, 2016 | Volume: 24 | Issue: 2 | Pages: e167-e176

10.1097/mjt.0000000000000387 | PMID 27148676 Get It

Background and Aims: Fatigue is a common symptom of primary biliary cirrhosis (PBC), and is associated with an impaired quality of life. Study Question: No studies have assessed the use of modafinil in fatigue related to PBC in a controlled manner. Study Design, Measures, and Outcomes: A randomized, double-blind, placebo-controlled study was conducted to determine the safety and efficacy of modafinil for the treatment of fatigue in PBC. Forty patients were randomized to modafinil (n = 20) or placebo (n = 20) for 12 weeks. A verbal report of fatigue for at least 6 months was required for enrollment. Modafinil was administered at 100 mg by mouth once daily; a change by 50 mg every 2 weeks (maximum: 200 mg once daily) was allowed, depending on the subject's response to treatment. The primary outcome was defined as a ≥50% improvement in fatigue severity [quantified by the Fisk Fatigue Impact Scale (FFIS)] after 12 weeks of treatment, compared with baseline values. Results: Thirty-three PBC patients completed the study. After 12 weeks of therapy, only 5 patients had a ≥50% reduction in FFIS scores: 3 patients (17.6%) in the modafinil arm and 2 (12.5%) in the placebo arm (P = 1.00). Change in median FFIS score was not statistically different between patients in the 2 treatment groups (P = 0.36). Modafinil was associated with minimal adverse events (headaches, diarrhea, and rash). Conclusions: In patients with PBC who have fatigue, treatment with modafinil for 12 weeks was safe and fairly well tolerated; however, it did not result in beneficial effects on fatigue compared with patients treated with placebo (CONSORT Table 1). ClinicalTrials.gov identifier NCT00943176.
Primary sclerosing cholangitis
Silveira, Marina G., Lindor, Keith D.

Mayo Clinic

Canadian Journal of Gastroenterology | March 15, 2016 | Volume: 22 | Issue: 8 | Pages: 689-698

10.1155/2008/824168 | PMID 18701947 Get It

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts, resulting in end-stage liver disease and reduced life expectancy. PSC primarily affects young and middle-aged men, often in association with underlying inflammatory bowel disease. The etiology of PSC includes immune-mediated components and elements of undefined nature. A cholestatic picture of liver biochemistries with elevations in serum alkaline phosphatase, nonspecific autoantibodies such as perinuclear antineutrophilic antibody, antinuclear antibodies and smooth muscle antibodies, and diffuse multifocal biliary strictures, resulting in a ‘beaded’ appearance on radiographic studies, are the hallmarks of the disease. No effective medical therapy is currently available, although clinical studies are in progress. Ursodeoxycholic acid at high doses (28 mg/kg/day to 30 mg/kg/day) is the most promising agent but is unproven so far. Liver transplantation is currently the only life-extending therapy for patients with end-stage disease, although recurrent disease can be observed in the transplanted liver. The multiple complications of PSC include pruritus, fatigue, vitamin deficiencies, metabolic bone disease, peristomal varices, bacterial cholangitis, dominant biliary strictures, gallbladder stones and polyps, and malignancy, particularly cholangiocarcinoma, which is the most lethal complication of PSC.
Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis
Momah, Njideka, Silveira, Marina G., Jorgensen, Roberta A., Sinakos, Emmanouil , Lindor, Keith D.

Mayo Clinic

Liver International | December 5, 2011 | Volume: 32 | Issue: 5 | Pages: 790-795

10.1111/j.1478-3231.2011.02678.x | PMID 22136310 Get It

AbstractBackgroundBiochemical tests have been recommended as endpoints for clinical trials in primary biliary cirrhosis (PBC) because the use of liver transplantation and death as endpoints in ursodeoxycholic acid (UDCA) therapeutic trials is unfeasible. The best inclusion criteria cut‐off values and cut‐off for demonstrating treatment success have not been defined.AimOur aim was to determine the optimal biochemical values for patient inclusion and to define values for treatment success in therapeutic trials.MethodsWe performed a retrospective review of 73 patients with PBC treated with UDCA followed over 36 months. Following one year of UDCA therapy, the likelihood of developing clinical endpoints of varices, ascites, encephalopathy, death or transplantation over the ensuing two years, based on degrees of elevation of biochemical markers, was analyzed using chi‐square or Fisher's exact test.ResultsPatients with ALP≥2 X upper limit of normal (ULN) had a 2‐fold greater likelihood of developing endpoints compared to patients with lower values (23% versus 11%), (p < 0.05). Patients with bilirubin > 1 mg/dL were 4 times more likely to develop endpoints compared to those with lower values (33% versus 8%), (p = 0.02). These values help identify the patient population for adjunctive therapy trials. Patients with ALP ≤1.67 X ULN and bilirubin ≤1mg/dL demonstrated the least likelihood of reaching adverse clinical endpoints and can be used to define treatment success.ConclusionOptimal ALP and Bilirubin levels can be used as appropriate biochemical criteria for patient selection and defining treatment success in future clinical trials in patients with PBC.
A Patient with Primary Biliary Cirrhosis and Elevated LDL Cholesterol
Foley, Kevin F , Silveira, Marina G., Hornseth, Jean M, Lindor, Keith D. , McConnell, Joseph P.

Mayo Clinic

Clinical Chemistry | December 23, 2008 | Volume: 55 | Issue: 1 | Pages: 187-192

10.1373/clinchem.2008.108720 | PMID 19106186 Get It